N4 PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.775 GBX | -6.06% |
|
-8.82% | -8.82% |
| 04-25 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
| 04-23 | N4 Pharma loss widens but "great optimism" remains | AN |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 4.32M 5.4M 432M |
|---|---|---|---|---|---|
| Net income 2021 | -1M -1.25M -100M | Net income 2022 | -1M -1.25M -100M | EV / Sales 2021 | - |
| Net cash position 2021 | 1.78M 2.23M 178M | Net cash position 2022 | 1.92M 2.4M 192M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-5.22
x | P/E ratio 2022 |
-3.35
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on N4 Pharma Plc
More press releases
| 1 day | -6.06% | ||
| 1 week | -8.82% | ||
| Current month | +19.23% | ||
| 1 month | +14.81% | ||
| 3 months | -11.43% | ||
| 6 months | -8.82% | ||
| Current year | -8.82% |
1 week
0.75
0.92
1 month
0.600.95
Current year
0.601.50
1 year
0.602.20
3 years
0.6010.43
5 years
0.6016.00
10 years
0.6035.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 31/12/13 | |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 46 | 13/07/20 | |
| Founder | 59 | 31/12/13 | |
Chris Britten
CHM | Chairman | - | 19/05/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.775 | -6.06% | 611,345 |
| 25/04/24 | 0.825 | 0.00% | 3,285,001 |
| 24/04/24 | 0.825 | -2.94% | 823,510 |
| 23/04/24 | 0.85 | 0.00% | 4,804,558 |
| 22/04/24 | 0.85 | 0.00% | 849,442 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes
N4 Pharma Plc is a United Kingdom-based specialist pharmaceutical company. The Company is focused on developing a silica nanoparticle delivery system to improve the cellular delivery of cancer treatments and vaccines. The Company is engaged in the development and commercialization of medicines through its delivery system, Nuvec. Nuvec is a silica nanoparticle technology with a patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical Phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. The Companyâs wholly owned subsidiaries include N4 Pharma UK Limited.
Sector
Pharmaceuticals
Calendar
07/05/2024
- Business Update Call
| 1st Jan change | Capi. | |
|---|---|---|
| -8.82% | 2.59M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ONZ Stock
